| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Wang Jonathan Jian | Director | C/O IMAGENEBIO, INC., 12526 HIGH BLUFF DRIVE, SAN DIEGO | /s/ Jotin Marango, Attorney-in-Fact | 2025-08-15 | 0001555242 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IMA | Common Stock | Award | +144K | 144K | Jul 25, 2025 | Direct | F1, F2, F3 | |||
| transaction | IMA | Common Stock | Award | +971K | 971K | Jul 25, 2025 | By Engene Inc. | F1, F2, F4, F5 |
| Id | Content |
|---|---|
| F1 | Under the terms of the Agreement and Plan of Merger, dated as of December 23, 2024, by and among, the Issuer, Insight Merger Sub I, a wholly-owned subsidiary of the Issuer ("Merger Sub I"), Insight Merger Sub II, a wholly-owned subsidiary of the Issuer ("Merger Sub II") and Inmagene Biopharmaceuticals ("Legacy Inmagene") (the "Merger Agreement"), on July 25, 2025, Merger Sub I merged with and into Legacy Inmagene (the "First Merger"), with Legacy Inmagene surviving the First Merger as a wholly-owned subsidiary of the Issuer, and immediately after the First Merger, Legacy Inmagene merged with and into Merger Sub II, with Merger Sub II surviving the First Merger as a wholly-owned subsidiary of the Issuer (the "Second Merger" and together with the First Merger, the "Merger"). (continued in the next footnote). |
| F2 | Upon the closing of the Merger, each Legacy Inmagene ordinary and preferred share was converted into the right to receive 0.003051 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Ikena Oncology, Inc. ("Ikena") to ImageneBio, Inc. |
| F3 | Received in exchange for 47,142,857 Series Seed convertible preferred shares of Legacy Inmagene pursuant to the Merger Agreement. |
| F4 | Received in exchange for 318,313,306 ordinary shares of Legacy Inmagene pursuant to the Merger Agreement. |
| F5 | Engene Inc.'s sole shareholder is YJH Trust of which Trident Trust Company (HK) Limited serves as trustee. Dr. Wang's spouse and daughter are the sole beneficiaries of YJH Trust. Accordingly, Dr. Wang has an indirect pecuniary interest over the shares of the Issuer held by Engene Inc. Dr. Wang disclaims beneficial ownership of the shares held by Engene Inc. except to the extent of his pecuniary interest therein, if any. |
This Form 4 is being filed late due to delays in obtaining the reporting person's EDGAR codes.